semaglutide 20 mg Weight loss drug reduces risk of adverse cardiovascular events by 20% among overweight, obese patients GLP-1 weight-loss drugs may also

Clinical guidelines support GLP-1 prescribing for individuals with a BMI of 30 or higher, or a BMI of 27 with weight-related conditions like hypertension or type 2 diabetes

Always consult your healthcare provider before beginning any new supplement, especially if you are managing diabetes or taking other medications

The Synergy : Tirzepatide excels at glycemic control, while L-Carnitine has also been shown to support healthy insulin sensitivity and improve lipid profiles

ii) Cardiovascular death: Excluding the SOUL trial strengthened the effect (shifting from non-significant to significant), suggesting sensitivity to SOUL but moderate robustness due to consistent overall effect direction and magnitude